Clinical trials: Lipoprotein(a)
Coronary Heart Disease
Inclisiran Effectiveness in China: a Pragmatic Randomized Trial
The current study will be conducted to evaluate the real-world effectiveness of inclisiran relative to standard of care (SoC) in Chinese patients with coronary heart disease (CHD), not only with the low-density lipoprotein…
- Trial name
- V-INVINCIBLE (NCT06941792)
- Testing
- inclisiran sodium injection, Standard of Care
- Where
- 19 sites in China
- Volunteers
- 1,590 people
- Sponsor
- Novartis Pharmaceuticals
Adult Participants With Elevated Lipoprotein(a)
A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).
- Trial name
- NCT07640217
- Testing
- SYH2068 Dose 1, SYH2068 Dose 2, SYH2068 Dose 3
- Volunteers
- 120 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Dyslipidemia
The Effect of MK0859 on Lipoprotein Metabolism in Patients With Dyslipidemia (0859-026 AM3)
This study will investigate the effect of MK0859 on lipoprotein metabolism in patients with dyslipidemia already on statin therapy.
- Trial name
- NCT00990808
- Testing
- anacetrapib, Comparator: atorvastatin
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Atherosclerosis
SB-480848 In Subjects With Coronary Heart Disease
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of…
- Trial name
- NCT00269048
- Testing
- SB-480848
- Where
- 119 sites in United States, Argentina and 14 more
- Volunteers
- 969 people
- Sponsor
- GlaxoSmithKline
Cardiovascular Disease and Lipoprotein(a)
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
- Trial name
- NCT07517263
- Testing
- Pelacarsen (TQJ230)
- Where
- 646 sites in United States, Argentina and 38 more
- Volunteers
- 5,700 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular
Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)
Cardiovascular diseases (CVDs), especially atherosclerotic coronary heart disease and stroke, are the leading causes of death globally.
- Trial name
- NCT01232309
- Testing
- Chitin-Glucan, Low Dose Chitin-Glucan, Low Dose Chitin-Glucan + Olive Extract
- Where
- 3 sites in United States, Canada
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Stratum Nutrition
Hypercholesterolemia
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Primary Objective: To provide participants with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT) access to…
- Trial name
- NCT02476006
- Testing
- ALIROCUMAB SAR236553 (REGN727), ezetimibe, atorvastatin
- Where
- 153 sites in Austria, Belgium and 14 more
- Volunteers
- 998 people
- Sponsor
- Sanofi
Parkinson Disease
Lipoprotein Metabolism and Bacterial Lipopolysaccharide in Parkinson's Disease
Patients with Parkinson's disease (PD) present an impaired intestinal permeability with consequent lipopolysaccharide (LPS) translocation in the systemic circulation.
- Trial name
- LiMBaLiP (NCT03937284)
- Testing
- Patients not treated
- Where
- Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Milan
Type 2 Diabetes
A Diabetes Study to Treat A Population Previously Not at Target
This study will assess if customizing the start dose of rosuvastatin appropriate for the degree of LDL-C reduction required, would achieve LDL-C target of ≤ 2.0 mmol/L quickly with either no titration or just one titration step…
- Trial name
- ADAPT (NCT00747149)
- Testing
- Rosuvastatin
- Where
- 84 sites in Canada
- Volunteers
- 598 people
- Sponsor
- AstraZeneca
Hypertriglyceridemia
Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia
The objectives of this study are to assess the effects of 4 g/d prescription omega-3 acid ethyl esters (POM3), compared with a placebo, on indices of insulin sensitivity and secretion, as well as aspects of the fasting and…
- Trial name
- NCT01034540
- Testing
- POM3
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Provident Clinical Research
Familial Hypercholesterolemia
Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is an autosomal codominant single gene disorder caused by mutations in the LDL receptor gene (LDLR) that disrupt the normal clearance of LDL particles from the plasma.
- Trial name
- NCT02225340
- Where
- Canada
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Laval University
Healthy Participants
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults
The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.
- Trial name
- NCT07513571
- Testing
- AZD4954, Laroprovstat
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypercholesterolemia
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
The purpose of this study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS), in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00082251
- Testing
- Niacin extended release and simvastatin tablets
- Sponsor
- Kos Pharmaceuticals
End Stage Kidney Disease (ESKD)
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in…
- Trial name
- NCT07619820
- Testing
- CSL300
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSL Behring
Cardiovascular Disease and Lipoprotein(a)
Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)
The study is conducted to improve knowledge about the epidemiology of Lipoprotein(a) in patients with established cardiovascular disease (CVD).
- Trial name
- NCT03887520
- Testing
- Blood draw for Lp(a)
- Where
- 900 sites in United States, Argentina and 47 more
- Volunteers
- 49,001 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis
Effect of Dapagliflozin on Interleukin 10 in Sepsis
The goal of this observational study is to learn about the long-term effects of dapagliflozin as anti-inflammatory agents to improve organ dysfunction and decrease mortality on patients of both genders ageing 18 years or above…
- Trial name
- NCT07206160
- Volunteers
- 64 people
- Sponsor
- Minia University
Elevated Lipoprotein(a)
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAL0195 Injection in Participants With or Without Elevated Lipoprotein(a)
This is a randomized, double-blind, placebo-controlled, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of SAL0195 injection in participants with or without…
- Trial name
- NCT07804160
- Testing
- SAL0195 Injection 30 mg, SAL0195 Injection 100 mg, SAL0195 Injection 300 mg
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Sedentary Lifestyle, Hyperinsulinemia
Developing a Physiological Understanding of High Duration Activity
When muscles are not contracting, the local energy demand by muscle and use of specific fuels used to produce energy by oxidative metabolism are minimal.
- Conditions
- Sedentary Lifestyle, Hyperinsulinemia, Glucose Tolerance Impaired, Low-density-lipoprotein-type
- Trial name
- NCT05135234
- Testing
- Muscular Exercise
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Houston
Acute Coronary Syndrome, Lipoproteinemia
Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)
The aim of study is to examine the relationship between lipid subfractions, inflammation and structural-functional properties of the arterial wall in patients after myocardial infarction with high lipoprotein (a) (Lp (a)) levels…
- Conditions
- Acute Coronary Syndrome, Lipoproteinemia, Inflammation, Genetic Polymorphisms
- Trial name
- NCT04993664
- Testing
- Pelacarsen (TQJ230)
- Where
- Slovenia
- Sponsor
- University Medical Centre Ljubljana